Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Lung Neoplasms × lazertinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 11 Non-Small Cell Lung Cancer Metastatic 1 Metastatic Non-small Cell Lung Cancers 1 Lung Neoplasms 1 Lazertinib 1 Advanced Solid Tumors 1

Interventions

Carboplatin 174 Cisplatin 105 Pemetrexed 95 Paclitaxel 94 Docetaxel 89 Gemcitabine 81 Radiotherapy 77 Erlotinib Hydrochloride 54 Bevacizumab 48 Etoposide 46 durvalumab 36 pembrolizumab 34 Specimen Handling 26 Magnetic Resonance Spectroscopy 26 Nivolumab 25 Gefitinib 24 Radiosurgery 23 Irinotecan 23 Vinorelbine 22 Drug Therapy 22 Topotecan 20 osimertinib 19 atezolizumab 16 Surgical Procedures, Operative 14 Radiation 14 Cetuximab 14 Neoadjuvant Therapy 13 Filgrastim 12 Chemotherapy, Adjuvant 12 Celecoxib 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05701384 2023-01-27

Lazertinib 160mg in EGFR T790M NSCLC

Samsung Medical Center

Phase 2 Unknown

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡